Carmine Stengone, Contineum Therapeutics CEO and president
March 15, 2024 10:22 PM EDTUpdated March 18, 06:33 AM
Financing
Startups

Con­tineum Ther­a­peu­tics files for IPO with MS drug in PhII

Kyle LaHucik

Senior Reporter

Clin­i­cal-stage biotech Con­tineum Ther­a­peu­tics, which un­til re­cent­ly went by the name Pipeline Ther­a­peu­tics, on Fri­day re­vealed plans to go pub­lic un­der the Nas­daq tick­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times